Supratentorial Glioblastoma

Search with Google Search with Bing
Information
Disease name
Supratentorial Glioblastoma
Disease ID
Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
Genes Mutation Description Source Links
NCT ID Status Phase Summary Start date Completion date
NCT04479241 Active, not recruiting Phase 2 LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma October 21, 2020 March 2024
NCT03732352 Active, not recruiting Phase 2 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma November 28, 2018 October 1, 2025
NCT01430351 Active, not recruiting Phase 1 Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy September 14, 2011 September 30, 2025
NCT00884741 Completed Phase 3 Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma April 15, 2009 March 17, 2013
NCT02311920 Completed Phase 1 Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma April 16, 2015 December 22, 2022
NCT05052957 Recruiting Phase 2 hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) January 20, 2023 December 1, 2024
NCT03197506 Suspended Phase 2 Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma September 15, 2017 August 31, 2024
NCT03997136 Unknown status Prognostic Impact of Surgical Resection Extent for Supratentorial High Grade Gliomas. September 1, 2019 July 1, 2021
NCT04105374 Withdrawn Phase 2/Phase 3 Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma January 31, 2020 November 30, 2030